Fortune Favors the Diligent

    "Fortune Favors the Deligent" is the classical expression of traditional Chinese philosophy, those practicing its essence can succeed. At the era of agrarian civilization, diligence is the attribute of peasants, sowing seeds in the spring and harvest in the autumn after hard work. After entering the commercial times, the essence of "Fortune Favors the Deligent" remains the same. "Diligence" serves as the ladder of reaching life dreams and harvesting substantial wealth. Nowadays, it is the client who rewards our hard work and determine how much we harvest rather than the nature. The clients and market are changing all the time. Since Tofflon's foundation in 1993, she has been upholding the doctrine "Fortune Favors the Diligent" regardless of the changes in the market, and Tofflon's three strategies are coming into reality step by step under the guidance of it. Now, Tofflon had achieved mutual benefits and reciprocity with our customers in the past 30 years. The glorious journey of Tofflon can be divided into three independent ten years. Each ten years we encountered different challenges, and our diligence focuses on different aspects. Absolutely, Tofflon also gets the rewards from our clients in each ten years.


the Early Days of Tofflon

    In 1993, the east of China - Shanghai, an private enterprise was born.  Zheng, who ever worked in a state-owned enterprise, started his own brilliant career for a lifetime in a small institute of Minhang district. At that time, no one had ever thought that Tofflon , by virtue of the tenacity of “Fortune Favors the Deligent”, could achieve such glorious achievements, and reaching today's status in the field of pharmaceutical equipment and make contributions to the progress of China's pharmaceutical equipment.    

    Tofflon disstingushes herself from other enterprises. In the development of pharmaceutical equipment, Tofflon  achieved harmonious development with the industry, in the future days to come, Tofflon would make better achievements. 

    At the forefront of the era, looking back, with the courage of new entrepreneurs and  the precious harvest we possess, which have been turned into treasures, deeply hidden in the spiritual culture of Tofflon. Looking ahead, we are confident, and would like to work together with China's pharmaceutical equipment industry to create the next glorious 30 years, 50 years, 100 years ......


The Spring Breeze of Reform Comes from the Sea, and Tofflon Rises in the East

In 1992,  after Deng Xiaoping's Talks in the South,  China comprehensively carried out reform and opening up to promote socialist modernization. The last round of reform and opening up was mainly in the Pearl River Delta; this time, the Yangtze River Delta, led by Shanghai, stood at the forefront of reform and opening up. The term “entrepreneurship” has also become popular among government institutions, enterprises and public organizations. The craze for entrepreneurship and business is once again sprouting and booming. Many people chose to venture into the business world and embrace a completely new life.

Zheng, head of the equipment section of Shanghai Biochemical Pharmaceutical Factory, is one of the entrepreneurial army. Born in 1964, Zheng's zodiac is the dragon. After graduating from the Chemical Machinery Department of the Shanghai Institute of Applied Science and Technology (SIAST), he joined the profitable  state-owned enterprise. Probably under the influence of his grandparents who immigrated to Shanghai in the early years, the word “diligence” was deeply rooted in Zheng's heart, and six years after graduation he became the head of the equipment section. This was a very enviable position in the state-owned enterprises at that time.


 创业初期的郑效东 .jpg

Zheng's Younger Days

Looking back, Zheng was immerged  in previous tough entrepreneurship experience and the proudness of the fighting times. As the head of the equipment section, Zheng had been working with lyophilizers for 9 years, and he was quite clear with the production process and operations of  lyophilizers. However, using and manufacturing lyophilizers are two totally different things, and manufacturing a lyophilizer by himself would be a unprecedented challenge.

Embarked on an entrepreneurial journey,  Zheng could not predict whether it is a promising market in the future, one thing for sure is  that the production process of lyophilizer is really consummate and mysterious, less people know  lyophilizers, not to mention the lyophilization curve.They also did not expect the application in  TCM and antimicrobials - the earliest lyophilizers were used for biochemical medicines, and many of them were extracted from animal offal, which all went bad once the temperature is high.

    Entrepreneurship is extremely tough at the start. At that time, Tofflon could only survive by fine repairment of lyophilizers from different countries. At that time, an imported lyophilizer was in malfunction, and the foreign supplier gave a quotation of 20,000 euros to find a company that can repair it within 10 months. Tofflon took over the task by chance, after a round of careful investigation, the machine was successfully repaired by changing only one seal ring, which made the name of Tofflon remembered by the customers from then on, laying a foundation for the rise of Tofflon.


     1.创业初期采购物质(93).jpg 图片1.png

                                                                                                  the Predicab in Early Days                                          the 509 Institute                               


    Since 1994, Tofflon was located  at a satellite research institute named 509. Tofflon rented a small room in the factory. It was here where the first Tofflon lyophilizer was manufactured. At that time, every order was hard to come by, and Zheng's simplest wish was to manufacture high-quality lyophilizers and sell it! After all, there are so many workers have to feed themselves and support their families, survival is the top priority. Now the first lyophilizer has been decommissioned, from the photo, without exquisite outlook, just a variety of spare parts were disorderly presented  in front of people.


第一台冻干机.jpg 图片2.png

     Early Lyophilizer by Tofflon                                Group Photo of Early Tofflon Staffs

     

    The old staff of Tofflon are all delighted in talking about the early days of the entrepreneurship.  It is very common to work overtime all night long.

    Sometimes, the staff slept beside the machine,  when they worked overtime at night, they ate fast food and gathered around the condenser while solving technical problems, and no one felt bitter. On weekends, Tofflon staffs spontaneously go to small restaurants and ordered simple food, they encouraged each other with smile.

    In this way, Tofflon staffs united together to serve the customers and manufacture best lyophilizers regardless of fatigue, with full anticipation, Tofflon was known for its conscientiousness and diligence from then on.


微信图片_20210709162252.jpg

Caligrahpy in Zheng's Office


    Since the mid-1990s, China's pharmaceutical industry has undergone unprecedented changes. Under the environment of strict international requirements for pharmaceutical certification, GMP standards were introduced to China in 1998, and Zheng was very sensitive to the changes in the pharmaceutical market. Zheng, who has been working in the frontline for years, is very sensitive to the changes in the pharmaceutical market, and the standards of GMP have brought him unlimited thoughts.

    From Zheng's side, lyophilizer industry is very systematic and aseptic technology is an important part of it. Zheng conceived the relationship between GMP, asepsis and Tofflon, and another opportunity in his life came. The implementation of the new version of GMP regulations, this policy has changed the trajectory of the entire pharmaceutical equipment industry, the national pharmaceutical plant equipment upgrading and iteration helps Tofflon's sales exceeded ten million dollars for the first time.

 

2002年4月第200台冻干机下线.JPG  2002年12月第300台冻干机下线.jpg

The Grand Decommissioning Ceremony of the Lyophilizer

    

    After the total sales surpassed  ten million yuan, Tofflon didn't stop,  Tofflon aimed at the overseas market quickly. The facts proved that  Zheng's persistence on technological innovation can help accurately grasp the development trend of pharmaceutical equipment.

    At an exhibition in Germany, Tofflon team carefully studied the functions of the lyophilizer, and held meetings at night to record the technical problems with notebooks, discussing the possible functions of the lyophilizer in the future, and then Tofflon produced the first LYO series (SIP/CIP) lyophilizer with automatic cleaning and automatic sterilization functions in China.

    The history attested  the foresight of Zheng once again: domestic laws and regulations became more and more sound, automatic cleaning and sterilization became the standard of lyophilizers, and Tofflon's lyophilizers occupied the domestic market overnight. The outbreak of SARS in 2003 advanced the development of new drug production line, and the demand for new production equipment boomed for the second time, thus Tofflon reached a hundred million dollars of sales in that year.


Scheme the Configuration and Bear the Great Mission of Industrial Upgrade

“Entrepreneurship is really amazing. The top priority is survival before we reach 100 million sales, and after that Tofflon really starts to grow with so many talents and opportunities.” Zheng said  later.


1.jpg 

Zheng Xiaodong, the President of Tofflon Group

    

    In 2003, in the domestic pharmaceutical equipment users were only Chinese pharmaceutical enterprises, and foreign capital, sino-foreign joint venture pharmaceutical companies usually chose foreign equipment, Tofflon once again became the industry model - and the cooperative relationships with GSK, Merial and other pharmaceutical companies were established, which was a really inspiring start, China's pharmaceutical equipment successfully entered the foreign market.

    Since then, Tofflon started  to enter the international market.Tofflon's internationalization processes are mainly realized in three aspects: first, the international export volume is no less than the domestic market, at present, Tofflon's export volume has reached 20% of the total sales, and the expansion of the foreign market has been increasing; second, in order to form an inclusive corporate culture and become a real international first-class brand, the foreign staff share is no less than 20%; the third is to become one of the suppliers recognized by global mainstream pharmaceutical companies and renowned enterprises. Based on the development strategy, Tofflon experienced the first fifteen years of hard work, from freeze-drying machine to lyophilizer systematic transformation, becoming the leading domestic pharmaceutical equipment service provider in export volume, surpassing 100 million U.S. dollars for the first time.

    Tofflon embarked on the journey of systematization and internationalization ......


2011年上市仪式.JPG

Shenzhen Stock Exchange Listed

 

    In March 2008, Tofflon turned into a joint stock limited company, with a net asset of 99.01 million RMB converted into 60 million share capital, and after entering the capital market in 2011, the share capital increased to 80 million. On February 1, 2011, Tofflon entered the A-shares market with a high issue price of 86 yuan per share, becoming the first listed company in China's pharmaceutical equipment industry.

    Subsequently, Tofflon has been developing rapidly, step by step. From the lyophilization single machine successfully broke through the foreign automatic feeding and discharging technology, and successively completed the upstream and downstream product lines, including liquid dispensing, filling, light inspection, packaging of the whole line through.

    In 2013, after several years of accumulation and growth, Tofflon officially became the first pharmaceutical machinery industry enterprise with a marketing performance exceeding 1 billion in China. In the past decades, the history of Tofflon's growth is also the epitome of the  China's pharmaceutical equipment, from the backwardness and  impovershmentof the beginning, to today's brilliant achievements, China also developed into a great nation with considerable industrial scale and a complete range of pharmaceutical machinery. Through the internal and external extension and upstream and downstream integration, China's pharmaceutical equipment industry market share as well as the entire industry concentration is constantly improving, and has made renowned remarkable achievements. Through the continuous enhancement of centralization, China's pharmaceutical equipment industry will turn from high-speed growth to the stage of high-quality development stage, and to achieve rapid development.


Forture Favors the Diligent and Tofflon Shoulders Social Responsibilities

    After the outbreak of the Covid-19 in the Spring Festival of 2020, Tofflon Group actively shouldered the responsibility of the nation and the society. During the tough time of the epidemic, Tofflon and its employees always rushed to the front line of the fight against the epidemic. At that time, the research and development and progress of the new 2019-nCoV vaccine has always been a matter of close attention for mankind, and the development of the new 2019-nCoV vaccine in China brings hope to people.

 

    On the fifth day of the Chinese Spring Festival in 2020, Beijing Institute of Biological Products issued a special order to Tofflon: an unconventional task for the core process equipment for the production of the new 2019-nCoV vaccine. At that time, Tofflon's team was very clear about the urgency and honor of this task, and Tofflon has developed an extraordinary will, tacit teamwork, and solid and reliable technical skills in the course of one real battle after another!

    Being conscious of the severity of the epidemic, the Tofflon team stays highly active. The sooner the vaccine production line was completed, the sooner our people could stay away from the shadow of the epidemic. Han Jun, the general manager in charge of the raw liquid configuration equipment of Beisheng Institute, said in his memory, “The new 2019-nCoV vaccine  project is extremely important, and we can only succeed.” “The pickling and passivation process stage is somewhat dangerous, and you can't doze off at all, and the team consisted of several engineers can't sleep for 36 hours!” This is a true practice of the core value of “Fortune Favors the Diligent”.

    The comprehensive design was completed within 10 days, and the production, installation, commissioning of the entire project were finished within 45 days, the second phase of the order in September, hundreds of liquid distribution tanks, equipment, but also within 2 months to complete all.

The resumption of domestic work and the supply chain was difficult to be guaranteed at that time, under the circumstance, Tofflon integrated all the resource to ensure the progress, worked overtime all night, raced against time, only to shoulder the responsibilities.

    Many Tofflon employees worked around the clock. As a technician of the 2019-nCoV vaccine project of BeiJing Institute of Biological Products, Li Xia, a southerner, was really afraid of the cold in Beijing, and there was no heating in the pharmaceutical factory when she went there, so Li Xia and her colleagues just wrapped up a thick cotton jacket to work overtime all night, and when they were tired, they just leaned against the wall in the corner to rest for a little while, and they worked continuously for 11 days and slept for only two or three hours every day, and finally completed the acceptance of the project successfully. we have lived up to the high expectations of our customers, the Party and the country for Tofflon, which is a good result for the Chinese people. In addition to Sinopharm national vaccine & serum institute's new 2019-nCoV vaccine, Tofflon has demonstrated “Chinese speed” and the integration of localized equipment to the world in many application scenarios around the world, such as Chengdu Westvac recombinant protein process route 2019-nCoV vaccine project, inactivated vaccine project of  Sinovac Biotech Ltd. mRNA process route vaccine project of Suzhou ABOGEN, and the new 2019-nCoV vaccine project of Russia's R-PHARM Satellite 5, etc. Tofflon has also shown “Chinese speed” and the integration of localized equipment to the world, as well as  the strong service capability of the Chinese localized equipment integration service provider. This year ,Tofflon impressed China and even the world in the history of the development of pharmaceutical equipment.

    In 2020, Tofflon received a letter of thanks from the United Front Department of the Shanghai Municipal Committee of the Communist Party of China (CPC), Tofflon was praised  for its contributions during the epidemic. In September, Shanghai Municipal Party Committee and Municipal Government awarded Tang Huixing, Vice President and Secretary of the Party Committee, with the honorary title of “Shanghai Advanced Individual in Fighting against the New Crown Epidemic”.

    2021, China Association for Vaccines issued the “Decision on the Notification and Commendation of Groups and Individuals with Outstanding Performance in the Fight Against the Epidemic (the First Batch)”, in which Shanghai Tofflon Technology Co. Ltd. was awarded the honorary title of “Outstanding Performance Anti-epidemic Group”, and Hu Jianjun, Program Manager of Shanghai Tofflon Science and Technology Co. Ltd.  In the “Decision on Commending the Groups and Individuals with Outstanding Performance in the Anti-epidemic Work (the Second Batch)” issued on May 30, Cheng Jinsheng and Huang Feng, General Managers of Tofflon Life Science and Technology Co.ltd were awarded the honorary title of “Individuals with Outstanding Performance in the Anti-epidemic Work”.

    At present, China is providing vaccine assistance to 80 countries and 3 international organizations around the world, while exporting vaccines to more than 40 countries and cooperating with more than 10 countries in vaccine R&D and production. Every time we see the eye-catching logo of Tofflon in the CCTV report, and the new  2019-nCoV vaccine produced by Chinese pharmaceutical factories using the equipment provided by China National Pharmaceutical Equipment Corporation being exported to the domestic and overseas market, all the Tofflon staffs feel highly proud and honored.

    Adhering to the mission of professional technology to serve human health, Tofflon responded rapidly and resolutely implements the key speeches and instructions of General Secretary Xi Jinping on epedemic prevention and control, plays an active role in this epidemic prevention and control, and earnestly fulfills its social responsibility. 

    In the future, Tofflon will, as in the past, continue to make efforts to carry forward the spirit of "God rewards diligence ", and shoulder social responsibility actively, and continue to make contributions in major public health, and bring an end to the global epidemic as soon as possible.


Concerted Efforts Lead to a Promising Future

    Nowadays, Tofflon, focusing on the next-generation drug manufacturing platform, is an integrated solution  provider for process science research, smart plant design and capability. While making progress, Tofflon has rapidly configurated and developed two major sections, namely, medical equipment and food engineering, and now Tofflon has achieved brilliant accomplishment. This demonstrates the excellence and advancement of China's pharmaceutical equipment enterprises, we can not only advancing our pharmaceutical industry technology, but also achieving synchronized progress with other industries!


May 2022|Tofflon

Copyright © 2020-2021东富龙科技集团股份有限公司 All Rights Reserved. 沪ICP备13216461号-1